These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 9075803)

  • 1. Effects of pramlintide, an analog of human amylin, on plasma glucose profiles in patients with IDDM: results of a multicenter trial.
    Thompson RG; Peterson J; Gottlieb A; Mullane J
    Diabetes; 1997 Apr; 46(4):632-6. PubMed ID: 9075803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of 14 days' subcutaneous administration of the human amylin analogue, pramlintide (AC137), on an intravenous insulin challenge and response to a standard liquid meal in patients with IDDM.
    Kolterman OG; Schwartz S; Corder C; Levy B; Klaff L; Peterson J; Gottlieb A
    Diabetologia; 1996 Apr; 39(4):492-9. PubMed ID: 8778001
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of 4 weeks' administration of pramlintide, a human amylin analogue, on glycaemia control in patients with IDDM: effects on plasma glucose profiles and serum fructosamine concentrations.
    Thompson RG; Pearson L; Kolterman OG
    Diabetologia; 1997 Nov; 40(11):1278-85. PubMed ID: 9389419
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The human amylin analog, pramlintide, corrects postprandial hyperglucagonemia in patients with type 1 diabetes.
    Fineman MS; Koda JE; Shen LZ; Strobel SA; Maggs DG; Weyer C; Kolterman OG
    Metabolism; 2002 May; 51(5):636-41. PubMed ID: 11979398
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The amylin analog pramlintide improves glycemic control and reduces postprandial glucagon concentrations in patients with type 1 diabetes mellitus.
    Nyholm B; Orskov L; Hove KY; Gravholt CH; Møller N; Alberti KG; Moyses C; Kolterman O; Schmitz O
    Metabolism; 1999 Jul; 48(7):935-41. PubMed ID: 10421239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pramlintide reduces postprandial glucose excursions when added to regular insulin or insulin lispro in subjects with type 1 diabetes: a dose-timing study.
    Weyer C; Gottlieb A; Kim DD; Lutz K; Schwartz S; Gutierrez M; Wang Y; Ruggles JA; Kolterman OG; Maggs DG
    Diabetes Care; 2003 Nov; 26(11):3074-9. PubMed ID: 14578242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pramlintide: a human amylin analogue reduced postprandial plasma glucose, insulin, and C-peptide concentrations in patients with type 2 diabetes.
    Thompson RG; Gottlieb A; Organ K; Koda J; Kisicki J; Kolterman OG
    Diabet Med; 1997 Jul; 14(7):547-55. PubMed ID: 9223392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial.
    Ratner RE; Dickey R; Fineman M; Maggs DG; Shen L; Strobel SA; Weyer C; Kolterman OG
    Diabet Med; 2004 Nov; 21(11):1204-12. PubMed ID: 15498087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomized study and open-label extension evaluating the long-term efficacy of pramlintide as an adjunct to insulin therapy in type 1 diabetes.
    Whitehouse F; Kruger DF; Fineman M; Shen L; Ruggles JA; Maggs DG; Weyer C; Kolterman OG
    Diabetes Care; 2002 Apr; 25(4):724-30. PubMed ID: 11919132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of postprandial hyperglycemia in subjects with IDDM by intravenous infusion of AC137, a human amylin analogue.
    Kolterman OG; Gottlieb A; Moyses C; Colburn W
    Diabetes Care; 1995 Aug; 18(8):1179-82. PubMed ID: 7587855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramlintide reduces postprandial glucose excursions when added to insulin lispro in subjects with type 2 diabetes: a dose-timing study.
    Maggs DG; Fineman M; Kornstein J; Burrell T; Schwartz S; Wang Y; Ruggles JA; Kolterman OG; Weyer C
    Diabetes Metab Res Rev; 2004; 20(1):55-60. PubMed ID: 14737746
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of single doses of pramlintide on gastric emptying of two meals in men with IDDM.
    Kong MF; Stubbs TA; King P; Macdonald IA; Lambourne JE; Blackshaw PE; Perkins AC; Tattersall RB
    Diabetologia; 1998 May; 41(5):577-83. PubMed ID: 9628276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pramlintide lowered glucose excursions and was well-tolerated in adolescents with type 1 diabetes: results from a randomized, single-blind, placebo-controlled, crossover study.
    Chase HP; Lutz K; Pencek R; Zhang B; Porter L
    J Pediatr; 2009 Sep; 155(3):369-73. PubMed ID: 19464026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adjunctive therapy with the amylin analogue pramlintide leads to a combined improvement in glycemic and weight control in insulin-treated subjects with type 2 diabetes.
    Ratner RE; Want LL; Fineman MS; Velte MJ; Ruggles JA; Gottlieb A; Weyer C; Kolterman OG
    Diabetes Technol Ther; 2002; 4(1):51-61. PubMed ID: 12017421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pramlintide improved measures of glycemic control and body weight in patients with type 1 diabetes mellitus undergoing continuous subcutaneous insulin infusion therapy.
    Herrmann K; Frias JP; Edelman SV; Lutz K; Shan K; Chen S; Maggs D; Kolterman OG
    Postgrad Med; 2013 May; 125(3):136-44. PubMed ID: 23748514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Infusion of pramlintide, a human amylin analogue, delays gastric emptying in men with IDDM.
    Kong MF; King P; Macdonald IA; Stubbs TA; Perkins AC; Blackshaw PE; Moyses C; Tattersall RB
    Diabetologia; 1997 Jan; 40(1):82-8. PubMed ID: 9028722
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus.
    Singh-Franco D; Robles G; Gazze D
    Clin Ther; 2007 Apr; 29(4):535-62. PubMed ID: 17617279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pramlintide in the treatment of type 1 and type 2 diabetes mellitus.
    Ryan GJ; Jobe LJ; Martin R
    Clin Ther; 2005 Oct; 27(10):1500-12. PubMed ID: 16330288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of the amylin analogue pramlintide on hepatic glucagon responses and intermediary metabolism in Type 1 diabetic subjects.
    Orskov L; Nyholm B; Yde Hove K; Gravholt CH; Møller N; Schmitz O
    Diabet Med; 1999 Oct; 16(10):867-74. PubMed ID: 10547215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pramlintide as an adjunct to insulin therapy improves long-term glycemic and weight control in patients with type 2 diabetes: a 1-year randomized controlled trial.
    Hollander PA; Levy P; Fineman MS; Maggs DG; Shen LZ; Strobel SA; Weyer C; Kolterman OG
    Diabetes Care; 2003 Mar; 26(3):784-90. PubMed ID: 12610038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.